Quest PharmaTech (QPT) Stock Price, News & Analysis

Company Overview

Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Key Stats

• Today's Range: C$0.02 to C$0.02
• 50-Day Range: C$0.02 to C$0.03
• 52-Week Range: C$0.02 to C$0.05
• Volume: 10,000 shs
• Average Volume: 55,263 shs
• Market Capitalization: C$3.38 million
• P/E Ratio: 0.67
• Dividend Yield: 6.15%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: CVE:QPT
• CIK: N/A
• Web: www.questpharmatech.com
• Phone: +1-780-4481400
• Fax: N/A
• Employees: 147,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C$0.03
• Trailing P/E Ratio: 0.67
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$2.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -6.28%
• Return on Assets: -1.07%

Debt

• Debt-to-Equity Ratio: 4.35
• Current Ratio: 0.40
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 20.00
• Book Value: C$0.14 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 169,129,000
• Free Float: N/A
• Market Cap: C$3.38 million
• Optionable: Not Optionable
• Beta: -0.07